The prognosis and control of the efficacy of heparin therapy in patients with diabetic glomerulosclerosis

• Published in: Klinicheskaia meditsina Vol. 74; no. 2; p. 32
• Main Authors: Pyrig, L A, Lapchinskaia, I I, Belitskaia, G A, Lezhen, T I, Iakovenko, A M, Ishchenko, V M, Fedorova, N E
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 1996
• Subjects: Adult; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - complications; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Nephropathies - blood; Diabetic Nephropathies - drug therapy; Drug Evaluation; Female; Glomerulosclerosis, Focal Segmental - blood; Glomerulosclerosis, Focal Segmental - drug therapy; Hemostasis - drug effects; Heparin - therapeutic use; Humans; Male; Middle Aged; Prognosis; Time Factors
• ISSN: 0023-2149

3-week heparin treatment (25000 U/day) of 38 patients with diabetic glomerulosclerosis (DGS) produced positive results in 31 of them, was ineffective in 5 patients and induced complications in 2 cases. Prognostic criteria of heparin treatment efficacy basing on hemostatic changes on day 7 have been developed. Hemostasis was controlled most effectively in patients receiving heparin by a new graphic turbidimetric method capable of objective registration of clotting and fibrinolysis in one plasma portion. Because individual sensitivity to heparin widely varies and this variability manifests as early as first days of treatment, control over hemostasis system in heparin day dose 25000 U/day is advisable before treatment, on treatment day 3, 7 and on aftertreatment day 2.